Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Mar;42(3):442-7.
doi: 10.1136/gut.42.3.442.

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

E Kouroumalis  1 , P Skordilis, K Thermos, A Vasilaki, J Moschandrea, O N Manousos
Affiliations
Clinical Trial

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

E Kouroumalis et al. Gut. 1998 Mar.

Abstract

Background: Standard treatment of inoperable hepatocellular carcinoma has not been established. Somatostatin has been shown to possess antimitotic activity against a variety of non-endocrine tumours.

Aims: To assess the presence of somatostatin receptors in human liver and to treat advanced hepatocellular carcinoma with the somatostatin analogue, octreotide.

Methods: Somatostatin receptors were measured in liver tissue homogenates from patients with acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment. Groups were comparable with respect to age, sex, Okuda classification, presence of cirrhosis, and liver biochemistry and virology.

Results: Various amounts of somatostatin receptors were identified in liver tissue of all patients including those with hepatocellular carcinoma. Treated patients had an increased median survival (13 months versus four months, p = 0.002, log rank test) and an increased cumulative survival rate at six and 12 months (75% versus 37%, and 56% versus 13% respectively). Octreotide administration significantly reduced alpha fetoprotein levels at six months. When a multivariable Cox's proportional hazards model was fitted, variables associated with increased survival were: treatment administration, absence of cirrhosis, increased serum albumin, and small tumours. Treated patients clearly had a lower hazard (0.383) in the multivariate analysis.

Conclusions: Octreotide administration significantly improves survival and is a valuable alternative in the treatment of inoperable hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Somatostatin receptors in liver tissue. Patients with either low or high levels of receptors can be identified in all disease groups. HCC, hepatocellular carcinoma.
Figure 2
Figure 2
Survival curves for treated and non-treated patients with HCC.
Figure 3
Figure 3
Survival curves for treated and non-treated cirrhotics with HCC.
Figure 4
Figure 4
Liver ultrasound of a patient before (top panel) and after six months (bottom panel) of treatment with octreotide. Small satellite tumours have regressed while the large tumour remains unchanged.
Figure 5
Figure 5
AFP concentration in the treated group. M, months.
See this image and copyright information in PMC

Comment in

References

    1. Cancer. 1996 Feb 15;77(4):635-9 - PubMed
    1. Cancer. 1995 Dec 1;76(11):2202-10 - PubMed
    1. J Hepatol. 1996 Mar;24(3):293-300 - PubMed
    1. Anal Biochem. 1976 May 7;72:248-54 - PubMed
    1. Lancet. 1978 Dec 9;2(8102):1217-9 - PubMed

Publication types

MeSH terms